ÂÜÀòÂÒÂ×

Lynn Seely, M.D. has served as a member of the board of directors since May 2021. Dr. Seely currently serves as a member of the board of directors of Blueprint Medicines Corp., a publicly-traded pharmaceutical company focused on precision medicine. From June 2016 to January 2021, Dr. Seely served as President, Chief Executive Officer and a member of the board of directors of Myovant Sciences, a biotechnology company, focused on redefining care for women and for men by developing and commercializing innovative therapies such as ÂÜÀòÂÒÂ×OVYX (relugolix) for men with advanced prostate cancer. From March 2005 to October 2015, Dr. Seely served as Senior Vice President and Chief Medical Officer of Medivation, a biotechnology company, where she led the development of XTANDI (enzalutamide) from the first-in-human clinical trial through global approvals for men with castration-resistant prostate cancer. Dr. Seely received an M.D. from the University of Oklahoma College of Medicine and a B.A. in Journalism from the University of Oklahoma. Dr. Seely completed her residency and served as chief resident in internal medicine at Yale-New Haven Hospital, and she completed her fellowship in endocrinology and metabolism at the University of California, San Diego.